©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Identification, Characterization, and Comparison of the Calmodulin-binding Domains of the Endothelial and Inducible Nitric Oxide Synthases (*)

(Received for publication, September 26, 1995; and in revised form, December 5, 1995)

Richard C. Venema (1)(§) Hassan S. Sayegh (2) Jonathan D. Kent (2) David G. Harrison (2)

From the  (1)From Vascular Biology Center, Medical College of Georgia, Augusta, Georgia 30912 and (2)Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia 30322

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

The calmodulin (CaM)-binding regions in bovine endothelial nitric oxide synthase (eNOS) and murine inducible nitric oxide synthase (iNOS) are identified in this study as eNOS residues 493-512 and iNOS residues 501-532. Peptides corresponding to eNOS 493-512 and iNOS 501-532 produce a Ca-dependent, electrophoretic mobility shift of CaM on 4 M urea gels. The two peptides are also potent inhibitors of the CaM-mediated activation of neuronal nitric oxide synthase and have dissociation constants for CaM binding of 4.0 and 1.5 nM, respectively. Substitution of eNOS and iNOS CaM-binding domains in eNOS/iNOS chimeric proteins produces major alterations in the Ca and CaM dependence of the intact enzymes expressed and purified from a baculovirus/Sf9 insect cell system. Replacement of aligned iNOS sequence with eNOS 493-512 creates a functional, chimeric iNOS that is both Ca- and CaM-dependent. Replacement of aligned eNOS sequence with iNOS 501-532 creates a functional, chimeric eNOS that is CaM-independent but that remains Ca-dependent. Specific amino acid residues critical for CaM binding by eNOS are also identified in this study as Phe-498, Lys-499, and Leu-511 in the bovine eNOS sequence.


INTRODUCTION

Nitric oxide (NO) (^1)is produced in various tissues by the oxidation of L-arginine in a reaction catalyzed by the enzyme NO synthase (NOS). Three distinct isoforms of NOS have been identified by cDNA cloning and sequencing. NOS cDNAs for the three isoforms derived from brain (1) , macrophage(2, 3, 4) , liver(5) , and endothelial cells (6, 7, 8, 9, 10) show about 50% identity in deduced amino acid sequence. Each of the sequences contains conserved regions that correspond to functional domains for binding of heme, calmodulin (CaM), FMN, FAD, and NADPH (11) . Type I neuronal NOS (nNOS) and Type III endothelial NOS (eNOS) are distinguished from Type II inducible NOS (iNOS) in that both are Ca-dependent, constitutive enzymes. nNOS and eNOS are activated in neurons, endothelial cells, and certain other cell types by agonist-stimulated elevation of intracellular Ca and resultant binding of Ca/CaM. In contrast, NO production by iNOS is thought to be Ca-independent. iNOS is induced in macrophages, as well as in other cells such as hepatocytes (12) and vascular smooth muscle (13) , in response to cytokines and bacterial endotoxin. The enzyme is tonically active once induced. However, despite the fact that it is a Ca-independent enzyme, iNOS contains a CaM-binding domain and CaM functions as subunit of the enzyme, remaining tightly bound even in the absence of elevated intracellular Ca(14) . Divergent sequences in the CaM-binding domains of the constitutive and inducible NOS isoforms, therefore, may produce major differences in the enzymes in terms of both their Ca-dependence and reversibility of CaM binding.

High affinity CaM-binding domains thus far identified have very limited degrees of sequence homology. These domains do, however, possess a number of common structural features. CaM-binding regions are typically contained within a short stretch of 15-20 contiguous amino acids that form a basic, amphiphilic alpha-helix within the target protein. Positively charged residues and hydrophobic residues are sequestered on opposite sides of the helix(15) . A sequence with these characteristics has been identified in nNOS (residues 725-747 of the rat cerebellar sequence) as the CaM-binding region of this enzyme(16, 17) . It has therefore been assumed that homologous sequences within eNOS and iNOS represent the CaM-binding domains of these enzymes(11) . eNOS and iNOS CaM-binding domains, however, have never been definitively identified or characterized. Furthermore, the CaM-binding domain of iNOS may be atypical as has been described for certain other proteins that bind CaM in a Ca-independent manner. The CaM-binding domain of the -subunit of phosphorylase kinase, for example, consists of two closely adjacent but noncontiguous subdomains(18) . The presence of two separated CaM-binding domains within the same polypeptide has also been reported for adenylate cyclase from Bordetella pertussis(19) .

In the present study, we have experimentally defined and characterized the CaM-binding domains of eNOS and iNOS. Studies with synthetic peptides and with eNOS/iNOS chimeric proteins provide insight into the molecular basis for differences in the Ca and CaM dependence of these two important enzymes.


EXPERIMENTAL PROCEDURES

Materials

Synthetic peptides were obtained from the Emory University Microchemical Facility. Peptides used were >95% pure as determined by high performance liquid chromatography. Spodoptera frugiperda Sf9 cells, baculovirus transfer vector pVL1393, and Baculogold viral DNA were purchased from Pharmingen (San Diego, CA). 2`, 5`-ADP-Sepharose was obtained from Pharmacia Biotech Inc. AG 50W-X8 cation exchange resin, protein dye reagent, and electrophoresis reagents were from Bio-Rad. L-[^14C]Arginine was purchased from Amersham Corp. RAW 264.7 macrophages were obtained from American Type Culture Collection. Sequenase 2.0 was a product of U. S. Biochemical Corp. cDNA for murine macrophage iNOS (3) was kindly provided by Dr. C. J. Lowenstein (Johns Hopkins University). cDNA for human nNOS (20) was a generous gift of Dr. J. S. Pollock (Abbott Laboratories).

Gel Mobility Shift Assays

High affinity binding of peptides to CaM was demonstrated by gel mobility shifts of CaM on 4 M urea-15% polyacrylamide gels. Gels were run in the presence of either 0.1 mM CaCl(2) or 2 mM EGTA in order to determine the Ca dependence and stoichiometry of binding according to the method described by Erickson-Viitanen and DeGrado(21) .

Quantitation of Binding Affinities of Peptide: Calmodulin Complexes

Dissociation constants for CaM binding of the eNOS 493-512 peptide and the iNOS 501-532 peptide were determined by competition assays with nNOS according to the procedure described by Erickson-Viitanen and DeGrado (21) for competition with myosin light chain kinase. Dissociation constants were estimated from the midpoints of the activation curves where the following equation is valid:

where [P(T)] is the total concentration of added peptide (20 nM) and [CaM] and K are concentrations of calmodulin required to reach half-maximal activation in the presence and the absence of peptide, respectively.

Preparation of Recombinant DNA Constructs for Baculovirus Expression of Recombinant Proteins

cDNA sequences encoding wild-type bovine eNOS(8) , wild-type murine iNOS(3) , and wild-type human nNOS (20) were subcloned into the EcoRI site of the plasmid transfer vector pVL1393. Chimeric cDNA sequences were created from the wild-type sequences in the transfer vector by insertional mutation using the polymerase chain reaction-based splicing-by-overlap-extension technique described by Ho et al.(22) . For the inducible (I) 501-523 eNOS protein, wild-type bovine eNOS sequence encoding residues 493-512 (TRKKTFKEVANAVKISASLM) was replaced by sequence encoding murine iNOS residues 501-523 (RPRRREIRFRVLVKVVFFASMLM). For the I 501-532 eNOS protein, wild-type bovine eNOS sequence encoding residues 493-521 (TRKKTFKEVANAVKISASLMGTLMAKRVK) was replaced by sequence encoding murine iNOS residues 501-532 (RPRRREIRFRVLVKVVFFASMLMRKVMASRVR). For the endothelial 493-512 iNOS protein, wild-type murine iNOS sequence encoding residues 501-523 was replaced with bovine eNOS sequence encoding residues 493-512. The precise, in-frame exchange of DNA sequence in the chimeric constructs was confirmed by dideoxy chain termination sequencing with Sequenase 2.0.

Expression, Purification, and Characterization of NOS Proteins

Recombinant pVL1393 transfer vectors encoding either wild-type eNOS, I 501-523 eNOS, I 501-532 eNOS, wild-type iNOS, endothelial 493-512 iNOS, or wild-type nNOS were separately cotransfected with Baculogold viral DNA into Sf9 insect cells in order to produce a high titer recombinant viral stock for use in subsequent infections of Sf9 cells. Infection of cells and purification of the six overexpressed proteins was carried out as described previously for wild-type eNOS(23) . High level expression of wild-type iNOS in Sf9 cells was achieved by addition of 1 mM N-nitro-L-arginine methyl ester to the culture medium to inhibit the overexpressed enzyme and thereby reduce the toxic effects of excessive NO production. Proteins were purified by 2`,5`-ADP-Sepharose chromatography and were >90% pure as determined by Coomassie staining of purified proteins separated on SDS-polyacrylamide gels. Enzyme activities were determined by measuring the rate of conversion of L-arginine to L-citrulline under conditions described previously(23) . Native, wild-type iNOS was also purified from RAW 264.7 macrophages by 2`,5`-ADP-Sepharose chromatography as described by Stuehr et al.(24) following activation of the cells (16 h) with Escherichia coli lipopolysaccharide (2 µg/ml) and recombinant murine interferon- (100 units/ml).


RESULTS AND DISCUSSION

Identification of eNOS and iNOS CaM-binding Sequences by Gel Mobility Shift Assays

Based on computer alogorithms that search for sequences of appropriate length, charge, hydrophobicity, and helical hydrophobic moment (25) the CaM-binding domain of bovine eNOS has been variously identified as either residues 493-512(6) , residues 496-512(8) , or residues 496-519(7) . The CaM-binding region of human eNOS has been predicted as residues 489-512(10) . Sequence analysis has also been used to predict the iNOS CaM-binding domain as murine residues 503-532(2) , murine residues 504-522(3) , or human residues 507-525(5) . Identification of the eNOS CaM-binding domain as residues 493-512 is likely correct because we have shown that deletion of this region results in loss of CaM-binding capacity of the purified mutant enzyme(23) . It is conceivable, however, that loss of binding by the deletion mutant is due to secondary effects of deletion on overall three-dimensional structure of the protein. Furthermore, no experimental evidence currently exists with regard to identification of the iNOS CaM-binding domain, and it is known that prediction of CaM-binding domains solely on the basis of computer analysis can result in misidentification, as has occurred previously with CaM-dependent adenylate cyclase (16) and caldesmon(26) . Therefore, in order to definitively establish the location of the CaM-binding sequences in eNOS and in iNOS, synthetic peptides representing the putative CaM-binding domains of these proteins were prepared and tested for their abilities to produce an electrophoretic mobility shift of CaM during polyacrylamide gel electrophoresis in 4 M urea(21) .

Depending on the charge and hydrophobicity of the peptide, high affinity binding of the peptide to CaM is detected by this method as a band with increased or decreased mobility relative to the unbound CaM band. In the presence of Ca, the electrophoretic mobility of CaM was retarded by a peptide corresponding to bovine eNOS residues 493-512 (Fig. 1A), suggesting that this sequence (identified previously by Lamas et al.(6) as the eNOS CaM-binding domain) contains all of the residues necessary for high affinity binding of Ca/CaM by eNOS. At a 2:1 ratio of CaM to peptide, half of the CaM formed a CaM-peptide complex. At a 1:1 ratio of CaM to peptide, all of the CaM was gel shifted, indicating a 1:1 stoichiometry of peptide-CaM complex formation. The eNOS 493-512 peptide, however, did not form a complex with CaM in the presence of the Ca chelator, EGTA, indicating that complex formation is Ca-dependent. Similar results were obtained when electrophoretic mobility shift assays were performed under nondenaturing conditions, indicating that 4 M urea is not required to demonstrate peptide-CaM complex formation.


Figure 1: Electrophoretic mobility shift of CaM by synthetic peptides. CaM (5 µg) was incubated with the indicated peptide in the presence of 0.1 mM CaCl(2) or 2 mM EGTA. Samples were then electrophoresed on 4 M urea-15% polyacrylamide gels containing either 0.1 mM CaCl(2) or 2 mM EGTA. The relative mobilities of CaM (indicated by arrows) and CaM-peptide complexes were visualized by Coomassie staining. Molar ratios of peptide:CaM of 0:1, 0.5:1, 1:1, and 2:1 are indicated. The results are representative of three separate experiments.



A synthetic peptide from iNOS that represents those residues in the murine iNOS sequence (501-523) that are aligned with bovine eNOS residues 493-512 (11) was also tested for its ability to bind either Ca/CaM or the Ca-deficient conformation of CaM (apoCaM). No complex formation was detected for the peptide and apoCaM. Furthermore, only trace amounts of Ca/CaM were retarded on the 4 M urea gel even at a 2:1 molar ratio of peptide to CaM (Fig. 1B). Thus, it appears that residues 501-523 of murine iNOS (which completely encompasses the 504-522 sequence identified by Lowenstein et al.(3) as the iNOS CaM-binding domain) does not represent the entire sequence necessary for either Ca-dependent or Ca-independent binding of CaM by iNOS. A longer 501-532 peptide sequence from murine iNOS (which encompasses the longer 503-532 sequence suggested by Xie et al.(2) as the iNOS CaM-binding domain) was also examined for its ability to bind either Ca/CaM or apoCaM. In contrast to the shorter sequence (501-523), the longer sequence (501-532) formed a 1:1 complex with CaM in the presence of Ca (Fig. 1C). Residues 524-532 in iNOS, therefore, which are located outside of the iNOS sequence aligned with the complete eNOS CaM-binding sequence, appear to be necessary for high affinity binding of CaM by the enzyme. Interestingly, no peptide-CaM complex formation occurred with the longer peptide in the presence of 2 mM EGTA, indicating that CaM binding (even by the longer iNOS sequence) is Ca-dependent.

The Ca-dependence of CaM binding by the iNOS 501-532 sequence suggests at least three alternative possibilities with regard to the interaction of CaM with the intact iNOS enzyme. One possibility is that binding of CaM by iNOS (which occurs in many cell types under resting cell Ca levels) is not a truly Ca-independent event but requires low concentrations of Ca. A second possibility is that binding of CaM by iNOS involves two closely adjacent subdomains, as has been described previously for the -subunit of phosphorylase kinase(18) . Binding of CaM to each individual subdomain in phosphorylase kinase is Ca-dependent. However, synergism between the two adjacent subdomains in the intact protein produces extremely high affinity for CaM even in the absence of Ca. If this type of interaction were to occur between iNOS and CaM, a second unrecognized CaM-binding domain may exist in iNOS adjacent in the primary structure to the one predicted by computer alogorithm(25) . A third possible explanation of the gel shift data is that regions or domains in iNOS that are not adjacent to the CaM-binding domain in the protein primary structure (and that may be physically far removed in the tertiary structure of the macromolecule) are required to produce a binding interaction that is not dependent on the presence of Ca.

Inhibition of a CaM-dependent Target Enzyme by eNOS and iNOS Peptides

The putative CaM-binding domains of eNOS and iNOS were further characterized by using synthetic peptides to inhibit the Ca/CaM-dependent activation of human nNOS, purified from a baculovirus/Sf9 insect cell system. nNOS obtained by this method was >90% pure and completely Ca/CaM-dependent and had a specific activity comparable with that reported for the enzyme purified from brain (1 µmol of L-citrulline produced/mg/min)(27) . Dose-dependent effects of various peptides on nNOS activity were examined. The eNOS 493-512 and iNOS 501-532 peptides were both potent inhibitors of nNOS activity with IC values of 6 ± 2 nM and 2 ± 2 nM, respectively (mean ± S.D., n = 3). The shorter iNOS peptide (501-523) also inhibited nNOS but with a lower potency. The IC of the iNOS 501-523 peptide for nNOS was 9 ± 5 nM (mean ± S.D., n = 3). A peptide corresponding to residues 524-544 in the iNOS sequence, which overlaps with the 9 most carboxyl residues in the iNOS 501-532 peptide, was also inhibitory at 100-fold higher concentrations. This result confirms that iNOS residues 524-532 make important contributions to iNOS CaM binding, because these 9 residues by themselves appear to have a low but significant affinity for Ca/CaM. However, because the iNOS 501-523 peptide had a greater inhibitory potency for nNOS than did the 524-544 peptide, it appears that most of the residues that contribute to iNOS CaM binding are amino-terminal to residue 524.

The possibility that the murine iNOS sequence contains a second CaM-binding domain immediately adjacent to that contained between amino acids 501-532 was also investigated. Two 26-residue peptides representing murine iNOS sequence immediately amino-terminal (residues 475-500) and immediately carboxyl-terminal (residues 533-558) to the 501-532 sequence were prepared and tested for their abilities to inhibit nNOS. No inhibition was observed with either peptide even at peptide concentrations as high as 1000 nM. Therefore, if a second CaM-binding domain does exist in iNOS, it appears that it is not located adjacent to the first domain as in the case, for example, of the two subdomains of the -subunit of phosphorylase kinase(18) .

Quantitation of Binding Affinities of eNOS and iNOS Peptides

The eNOS and iNOS CaM-binding domains were also compared in terms of their dissociation constants for Ca/CaM. Competition assays employing the target enzymes, phosphodiesterase (28) and myosin light chain kinase(29) , have been used in previous studies to determine CaM-binding domain dissociation constants. In the present study, we have used competition assays with nNOS to determine the K(D) values of the eNOS 493-512 and iNOS 501-532 peptides for Ca/CaM binding. K(D) values were estimated by the method of Erickson-Viitanen and DeGrado (21) as 4.0 ± 1.2 nM and 1.5 ± 0.8 nM for the eNOS and iNOS sequences, respectively (mean ± S.D., n = 3). CaM-binding domains in many proteins have been narrowed down to sequences about 20 residues in length that bind CaM at least as tightly as the intact proteins themselves(15) . These domains typically have dissociation constants for reversible binding of Ca/CaM in the range of 1-10 nM, similar to the values determined in this study for the eNOS 493-512 and iNOS 501-532 sequences. The intact iNOS protein, however, is expected to have a much lower K(D) for CaM because CaM does not dissociate from intact iNOS even in the presence of high concentrations of EGTA or strongly denaturing conditions(14) . Thus, although iNOS does not appear to possess two closely adjacent CaM-binding subdomains like those found in phosphorylase kinase, it is likely that other portions of the iNOS molecule (other than residues 501-532 or adjacent sequences) also contribute to the irreversible association of CaM with iNOS.

Determination of Ca and CaM dependence of eNOS, iNOS, and Chimeric Enzymes

In order to gain additional insight into the molecular basis for differences between eNOS and iNOS with regard to their Ca-dependence and reversibility of CaM binding, the two intact proteins plus three different eNOS/iNOS chimeric proteins were characterized after expression and purification from a baculovirus/Sf9 insect cell system. Wild-type bovine eNOS was overexpressed in hemin-supplemented insect cells at the level of approximately 3% of total insect cell protein as described previously (23) . Similar high levels of expression of murine iNOS required that infected cells be treated with the NOS inhibitor, N-nitro-L-arginine to reduce the toxic effects of NO production by the tonically active enzyme. NO toxicity to Sf9 cells overexpressing the ``high output'' iNOS may explain the lower than expected levels of iNOS expression in a baculovirus system previously observed by other investigators(30) . In addition to the two wild-type enzymes, three different eNOS/iNOS chimeric proteins were also expressed and purified from the baculovirus system. A chimeric protein designated as I 501-523 eNOS was expressed in which the wild-type 493-512 sequence in eNOS was replaced by the iNOS 501-523 sequence. A second chimeric protein was expressed, designated as I 501-532 eNOS, in which the 493-521 sequence in eNOS was replaced by the iNOS 501-532 sequence. A final chimeric enzyme was expressed, designated as endothelial 493-512 iNOS, in which the 501-523 sequence in iNOS was replaced by the eNOS 493-512 sequence. Each of the five expressed proteins were purified to >90% homogeneity by affinity chromatography on 2`,5`-ADP-Sepharose. Purifications were carried out in buffer containing 2 mM EGTA in order to dissociate any CaM bound to the enzymes in a Ca-dependent manner. Interactions between mammalian NOS proteins and the CaM endogenously produced in insect cells are expected to be essentially identical to those that would occur with mammalian CaM, because CaM has been highly conserved throughout eukaryotic evolution. CaM primary sequences, for example, from bovine brain and from jellyfish are identical at 141 out of 148 of residues(31) . Furthermore, the purified NOS enzymes obtained from the baculovirus expression system are expected to be uncontaminated with any endogenous NOS expressed in insect cells because uninfected Sf9 cells were found to contain no detectable NOS activity.

Catalytic activity of each of the five purified NOS enzymes was measured in the presence of varying concentrations of exogenously added CaM (Fig. 2). Assays were carried out in the presence of Ca (2.5 mM) and in the absence of Ca (achieved by addition of 10 mM EGTA). Wild-type eNOS, purified from the baculovirus expression system, was completely dependent on both Ca and CaM (Fig. 2A). Wild-type iNOS, on the other hand, was completely CaM-independent as well as significantly (although not entirely) Ca-independent (Fig. 2B). Purified iNOS thus appears to contain irreversibly bound CaM, which does not dissociate from the enzyme even during purification in the presence of 2 mM EGTA. Moreover, purified iNOS was consistently found to be twice as active in the presence of Ca than in its absence. Although other investigators have reported previously that iNOS can be partially inactivated by EGTA(32, 33, 34) , many researchers currently assume that iNOS is completely unaffected by Ca chelation. iNOS activity determinations of tissue homogenates are thus routinely carried out in the presence of high concentrations of EGTA. Therefore, we sought to determine whether iNOS isolated from macrophages displays the same partial Ca dependence observed for the baculovirus-expressed enzyme. iNOS was purified from activated murine RAW 264.7 macrophages by the method used for purification of the baculovirus-expressed enzyme. iNOS activity of crude macrophage homogenates and of the purified macrophage-expressed enzyme was inhibited by 10 mM EGTA to approximately the same extent observed with the baculovirus-expressed enzyme. These results suggest that iNOS activity determinations that are performed in the presence of EGTA may underestimate enzyme activity by up to 2-fold.


Figure 2: Ca2+ and CaM dependence of wild-type and chimeric NOS enzymes. NOS activity was determined by estimating the rate of conversion of L-arginine to L-citrulline. Assays were performed in duplicate in the presence of varying concentrations of CaM and in the presence of either 2.5 mM CaCl(2) or 10 mM EGTA. Similar results were obtained in three different experiments.



Replacement of the CaM-binding sequence of eNOS (residues 493-512) with aligned sequence from iNOS (residues 501-523) resulted in creation of a chimeric enzyme that had properties distinct from both wild-type eNOS and wild-type iNOS (Fig. 2C). The I 501-523 eNOS chimeric enzyme was activated by both apoCaM and Ca/CaM. The iNOS 501-523 sequence by itself, however, was not sufficient to produce irreversible CaM-binding. Thus, I 501-523 eNOS (like wild-type eNOS) remained dependent on exogenously added CaM for activity. In contrast, the longer iNOS 501-532 sequence was sufficient to confer CaM independence on eNOS. I 501-532 eNOS (like wild-type iNOS) was completely independent of added CaM (Fig. 2D). An additional conclusion that can be drawn from the CaM-independence observed for I 501-532 eNOS is that regions in iNOS that are required for irreversible CaM binding (but that are located outside of residues 501-532) are also conserved in the eNOS enzyme. If these other putative domains did not exist in eNOS, I 501-532 eNOS would be expected to remain CaM-dependent (like wild-type eNOS). Interestingly, irreversible association of CaM with eNOS (observed with I 501-532 eNOS) was not sufficient to activate the enzyme in the absence of Ca (Fig. 2D). It appears that bound CaM must be in the Ca/CaM conformation in order to interact with eNOS in a manner that activates the enzyme. A final conclusion apparent from analysis of the chimeric enzymes is that the 501-523 region of iNOS (which was not sufficient to produce irreversible CaM binding in eNOS) is necessary for the Ca and CaM independence of iNOS. This is illustrated by the endothelial 493-512 iNOS chimeric enzyme, which was completely dependent on both Ca and CaM for catalytic activity (Fig. 2E).

Identification of Amino Acids Essential for CaM Binding by the eNOS CaM-binding Domain

The 493-512 sequence of bovine eNOS contains a number of hydrophobic and basic residues that may be involved in Ca/CaM binding by the enzyme. For example, as noted previously by Ikura et al.(35) , CaM-binding domains often share a common feature of containing either aromatic residues or long chain hydrophobic residues that are 14 residues apart in sequence and that form key contacts with CaM in CaM-enzyme complexes. Two such residues are found in eNOS at Phe-498 and Leu-511. These residues are also conserved in the sequences of iNOS, nNOS, smooth muscle myosin light chain kinase, and skeletal muscle myosin light chain kinase (Table 1). A third hydrophobic residue in eNOS at Val-505 is also conserved in iNOS, nNOS, smooth muscle myosin light chain kinase, and skeletal muscle myosin light chain kinase. This residue has also been shown to be important for CaM binding in CaM-myosin light chain kinase peptide complexes(35, 36) . In general, hydrophobic amino acids seem to play a more important role in CaM binding than do charged residues(37) . However, basic residues are invariably found in CaM-binding domains and one or more of these residues appear to contribute to CaM binding via electrostatic interactions between basic residues in the enzyme and acidic residues in the highly acidic CaM molecule(15) . Bagchi et al.(37) have noted previously that these basic residues are frequently located within CaM-binding domains at a position 13 residues carboxyl to the first hydrophobic residue. Basic residues are found in this position in the CaM-binding domains of smooth muscle myosin light chain kinase, skeletal muscle myosin light chain kinase, and nNOS. The eNOS enzyme, however, contains a serine at this position (Table 1). Other basic residues within eNOS that might be important determinants of CaM-binding include Arg-494, Lys-495, Lys-496, Lys-499, and Lys-506.



The importance of specific hydrophobic and basic residues to eNOS CaM binding was assessed using two different approaches. Peptides were prepared in which Phe-498, Val-505, Leu-511, Arg-494, Lys-495, Lys-496, Lys-499, and Lys-506 were each individually replaced by alanine residues. Mutated peptides were then compared with the wild-type peptide for their ability to gel shift CaM on 4 M urea gels as well as for their inhibitory potency for the CaM-mediated activation of nNOS. Peptides that were mutated at either Phe-498, Leu-511, or Lys-499 lost their capacity for high affinity binding of CaM, as evidenced by loss of CaM mobility shift on 4 M urea gels (Table 2). Furthermore, these same three peptides showed significantly lower potencies for inhibition of nNOS than did the wild-type peptide. The hydrophobic residues, Phe-498 and Leu-511, as well as the basic residue, Lys-499, thus appear to represent essential determinants of the eNOS/CaM interaction. Phe-498 appears to be especially important because mutation at this residue results in a 150-fold increase in the IC of the mutant peptide for inhibition of nNOS.




FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912-2500. Tel.: 706-721-2576; Fax: 706-721-9799.

(^1)
The abbreviations used are: NO, nitric oxide; NOS, nitric oxide synthase; eNOS, endothelial nitric oxide synthase; nNOS, neuronal nitric oxide synthase; iNOS, inducible nitric oxide synthase; CaM, calmodulin; I, inducible.


REFERENCES

  1. Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., and Snyder, S. H. (1991) Nature 351, 714-718 [CrossRef][Medline] [Order article via Infotrieve]
  2. Xie, Q., Cho, H. J., Calaycay, J., Mumford, R. A., Swiderek, K. M., Lee, T. D., Ding, A., Troso, T., and Nathan, C. (1992) Science 256, 225-228 [Medline] [Order article via Infotrieve]
  3. Lowenstein, C. J., Glatt, C. S., Bredt, D. S., and Snyder, S. H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6711-6715 [Abstract]
  4. Lyons, R. C., Orloff, G. J., and Cunningham, J. M. (1992) J. Biol. Chem. 267, 6370-6374 [Abstract/Free Full Text]
  5. Geller, D. A., Lowenstein, C. J., Shapiro, R. A., Nussler, A. K., Di Silvio, M., Wang, S. C., Nakayama, D. K., Simmons, R. L., Snyder, S. H., and Billiar, T. R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3491-3495 [Abstract]
  6. Lamas, S., Marsden, P. A., Li, G. K., Tempst, P., and Michel, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6348-6352 [Abstract]
  7. Sessa, W. C., Harrison, J. K., Barber, C. M., Zeng, D., Durieux, M. E., D'Angelo, D. D., Lynch, K. R., and Peach, M. J. (1992) J. Biol. Chem. 267, 15274-15276 [Abstract/Free Full Text]
  8. Nishida, K., Harrison, D. G., Navas, J. P., Fisher, A. A., Dockery, S. P., Uematsu, M., Nerem, R. M., Alexander, R. W., and Murphy, T. J. (1992) J. Clin. Invest. 90, 2092-2096 [Medline] [Order article via Infotrieve]
  9. Jannssens, S. P., Shimouchi, A., Quertermous, T., Bloch, D. B., and Bloch, K. D. (1992) J. Biol. Chem. 267, 14519-14522 [Abstract/Free Full Text]
  10. Marsden, P. A., Schappert, K. T., Chen, H. S., Flowers, M., Sundell, C. L., Wilcox, J. N., Lamas, S., and Michel, T. (1992) FEBS Lett. 307, 287-293 [CrossRef][Medline] [Order article via Infotrieve]
  11. Sessa, W. C. (1994) J. Vasc. Res. 31, 131-143 [Medline] [Order article via Infotrieve]
  12. Iida, S., Oshima, H., Oguchi, S., Hata, T., Suzuki, H., Kawasaki, H., and Esumi, H. (1992) J. Biol. Chem. 267, 25385-25388 [Abstract/Free Full Text]
  13. Perrella, J. A., Yoshizumi, M., Fen, Z., Tsai, J. C., Hsieh, C. M., Kourembanas, S., and Lee, M. E. (1994) J. Biol. Chem. 269, 14595-14600 [Abstract/Free Full Text]
  14. Cho, H. J., Xie, Q. W., Calaycay, J., Mumford, R. A., Swiderek, K. M., Lee, T. D., and Nathan, C. (1992) J. Exp. Med. 176, 599-604 [Abstract]
  15. O'Neil, K. T., and DeGrado, W. F. (1990) Trends Biochem. Sci. 15, 59-64 [CrossRef][Medline] [Order article via Infotrieve]
  16. Vorherr, T., Knöpfel, L., Hofmann, F., Mollner, S., Pfenffer, T., and Carafoli, E. (1993) Biochemistry 32, 6081-6088 [Medline] [Order article via Infotrieve]
  17. Zhang, M., and Vogel, H. J. (1994) J. Biol. Chem. 269, 981-985 [Abstract/Free Full Text]
  18. Dasgupta, M., Honeycutt, T., and Blumenthal D. K. (1989) J. Biol. Chem. 264, 17156-17163 [Abstract/Free Full Text]
  19. Ladant, D. (1988) J. Biol. Chem. 263, 2612-2618 [Abstract/Free Full Text]
  20. Nakane, M., Schmidt, H. H. H. W., Pollock, J. S., Förstermann, U., and Murad, F. (1993) FEBS Lett. 316, 175-180 [CrossRef][Medline] [Order article via Infotrieve]
  21. Erickson-Viitanen, S., and DeGrado, W. F. (1987) Methods Enzymol. 139, 455-478 [Medline] [Order article via Infotrieve]
  22. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59
  23. Venema, R. C., Sayegh, H. S., Arnal, J. F., and Harrison, D. G. (1995) J. Biol. Chem. 270, 14705-14711 [Abstract/Free Full Text]
  24. Stuehr, D. J., Kwon, N. S., and Nathan, C. F. (1990) Biochem. Biophys. Res. Commun. 168, 558-565 [Medline] [Order article via Infotrieve]
  25. DeGrado, W. F., Erickson-Viitanen, S., Wolfe, H. R., Jr., and O'Neil, K. T. (1987) Proteins 2, 20-33 [Medline] [Order article via Infotrieve]
  26. Zhan, Q., Wong, S. S., and Wang, C. L. A. (1991) J. Biol. Chem. 266, 21810-21814 [Abstract/Free Full Text]
  27. Bredt, D. S., and Snyder, S. H.. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 682-685 [Abstract]
  28. Cox, J. A., Comte, M., Fitton, J. E., and DeGrado, W. F. (1985) J. Biol. Chem. 260, 2527-2534 [Abstract]
  29. Edelman, A. M., Takio, K., Blumenthal, D. K., Hansen, R. S., Walsh, K. A., Titani, K., and Krebs, E. G. (1985) J. Biol. Chem. 260, 11275-11285 [Abstract/Free Full Text]
  30. Moss, D. W., Wei, X., Liew, F. Y., Moncada, S., and Charles, I. G. (1995) Eur. J. Pharmacol. 289, 41-48 [Medline] [Order article via Infotrieve]
  31. Jamieson, G. A., Jr., Hayes, A., Blum, J. J., and Vanaman, T. C. (1980) in Calcium-Binding Proteins: Structure and Function (Siegel, F. L., Carfoli, E., Kretsinger, R. H., MacLennan, D. H., and Wasserman, R. H., eds) pp. 165-172, Elsevier Science Publishers B.V., Amsterdam
  32. Stuehr, D. J., Cho, H. J., Kwon, N. S., Weise, M. F., and Nathan, C. F. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7773-7777 [Abstract]
  33. Stuehr, D. J., and Griffith, O. W. (1992) Adv. Enzymol. Relat. Areas Mol. Biol. 65, 287-346 [Medline] [Order article via Infotrieve]
  34. Nathan, C., and Xie, Q. W. (1994) Cell 78, 915-918 [Medline] [Order article via Infotrieve]
  35. Ikura, M., Clore, G. M., Gronenborn, A. M., Zhu, G., Klee, C. B., and Bax, A. (1992) Science 256, 632-638 [Medline] [Order article via Infotrieve]
  36. Meador, W. E., Means, A. R., and Quiocho, F. A. (1992) Science 257, 1251-1255 [Medline] [Order article via Infotrieve]
  37. Bagchi, I. C., Huang, Q., and Means, A. R. (1992) J. Biol. Chem. 267, 3024-3029 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.